Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1176/appi.ajp.2014.14060701r | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Phase 1b Dose Escalation Study of Sozinibercept Inhibition of Vascular Endothelial Growth Factors C and D With Aflibercept for Diabetic Macular Edema.
Transl Vis Sci Technol
December 2024
Opthea Limited, Melbourne, Victoria, Australia.
Purpose: Sozinibercept inhibits vascular endothelial growth factors (VEGFs) C and D. This study evaluated outcomes following switching from anti-VEGF-A monotherapy to intravitreal injections of three dose levels of sozinibercept in combination with aflibercept in patients with diabetic macular edema (DME).
Methods: A phase 1b, open-label, multicenter dose-escalation study with a 24-week follow-up.
Factors and Reasons Associated with Hesitating to Seek Care for Migraine: Results of the OVERCOME (US) Study.
Neurol Ther
November 2024
Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA.
Article Synopsis
- A significant number of individuals with migraines, 45.1%, hesitate to seek medical care, which could limit effective treatment and management of their condition.
- The OVERCOME (US) survey utilized machine learning and regression models to identify key factors influencing this hesitation, such as stigma and personal management efforts.
- Common reasons for not seeking help include a desire to self-manage migraines and beliefs that their headaches might not warrant professional attention.
Ipilimumab and nivolumab plus radioembolization as salvage therapy for atezolizumab and bevacizumab refractory hepatocellular carcinoma resulting in complete pathologic response.
Radiol Case Rep
November 2024
Division of Interventional Radiology, Mayo Clinic Florida, Jacksonville, Florida.
Article Synopsis
- Unresectable hepatocellular carcinoma (HCC) has a poor outlook when it doesn't respond to first-line immunotherapy, and second-line treatments like tyrosine kinase inhibitors only offer modest improvements.
- The effectiveness of combining local therapies, such as immunotherapy rechallenge, remains unclear for these patients, but radioembolization has shown promise when paired with immunotherapy.
- A reported case details a patient with aggressive HCC who, after failing previous treatments, achieved a complete pathologic response and is over two years without recurrence after receiving a combination of ipilimumab, nivolumab, and radioembolization.
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
N Engl J Med
July 2024
From the Metabolic Dysfunction-Associated Steatotic Liver Disease Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California at San Diego, La Jolla (R.L.), and Pacific Rim Pathology, San Diego (C.B.) - both in California; Eli Lilly (M.L.H., Y.T., B.B., D.A.R., A.N., M.C.B., A.H.), the Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine (R.V.), and the Department of Pathology and Laboratory Medicine, Indiana University (O.W.C.) - all in Indianapolis; the Texas Liver Institute, University of Texas Health, San Antonio (E.J.L.); the Department of Hepato-Gastroenterology and Digestive Oncology, Angers University Hospital, and Hemodynamics, Interaction of Fibrosis and Hepatic Tumor Invasiveness Laboratory, Structure Fédérative de Recherche Interactions Cellulaires et Applications Thérapeutiques 4208, Angers University - both in Angers, France (J.B.); the Division of Gastroenterology, Department of Medical Sciences, University of Turin, Turin, Italy (E.B.); the Department of Gastroenterology and Hepatology, Yokohama City University, Yokohama, Japan (M.Y.); and the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health and Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University School of Medicine, Richmond (A.J.S.).
Background: Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease associated with liver-related complications and death. The efficacy and safety of tirzepatide, an agonist of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, in patients with MASH and moderate or severe fibrosis is unclear.
Methods: We conducted a phase 2, dose-finding, multicenter, double-blind, randomized, placebo-controlled trial involving participants with biopsy-confirmed MASH and stage F2 or F3 (moderate or severe) fibrosis.
Machine learning identifies factors most associated with seeking medical care for migraine: Results of the OVERCOME (US) study.
Headache
September 2024
Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, USA.
Objective: Utilize machine learning models to identify factors associated with seeking medical care for migraine.
Background: Migraine is a leading cause of disability worldwide, yet many people with migraine do not seek medical care.
Methods: The web-based survey, ObserVational survey of the Epidemiology, tReatment and Care Of MigrainE (US), annually recruited demographically representative samples of the US adult population (2018-2020).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!